Greenwich LifeSciences 3Q 2026: EPS ($0.4) — 10-Q Summary

Greenwich LifeSciences reported no revenue, with a net loss of $5.81M and EPS of -$0.40 in Q3 2026. R&D costs rose 67% due to clinical expenses, while G&A costs fell 12%. The company is expanding its Phase III trial for GLSI-100 globally. Cash reserves were $5.9M, but additional capital is needed for long-term operations, according to the company.

Original reporting
Published Nov 16, 2026, 11:37 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 17, 2026, 12:43 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Greenwich LifeSciences 3Q 2026: EPS ($0.4) — 10-Q Summary — source image
Decision brief

The 30-second read

$GLSIBearishMed
01

Why it matters

For traders, the key decision inputs are the widened loss, the magnitude of R&D expense growth, and the explicit statement that additional capital is needed, which can affect valuation and financing expectations.

02

Market read

The 10-Q summary signals higher burn and runway risk while confirming continued Phase III expansion, creating a mixed but liquidity-negative setup.

03

What to watch

Cash at Sept. 30 is only a snapshot; investors will also weigh any subsequent financing, milestone payments, or changes in trial enrollment pace not captured in this brief.

Relevance 6/10Novelty 6/10Timing: after-hours/late-day 10-Q summary published Nov. 16, 2026

Background

The piece summarizes Greenwich LifeSciences’ 10-Q, highlighting lack of revenue, rising clinical spend, and liquidity constraints alongside Phase III trial activity.

Company-level read

Ticker impact

$GLSIBearishMedium confidence
Context

Greenwich LifeSciences reported a widened net loss and no revenue, with R&D up 67% and cash of $5.9M at Sept. 30, 2026.

Expected impact

Likely downside bias as investors price higher burn and potential capital needs, despite ongoing Phase III progress.

Evidence & confidence

The article provides concrete quarterly financial deterioration (net loss, R&D increase) and explicit liquidity warning (additional capital needed), which typically drives biotech risk repricing.

Market effects

Reinforces typical pre-revenue biotech investor focus on burn rate, clinical expense ramp, and runway versus trial expansion.

No clear regional macro linkage beyond US-listed biotech risk sentiment.

Phase III Europe expansion may modestly affect global breast-cancer trial sentiment, but the article is primarily company-specific.

Counterpoint

The R&D increase is tied to clinical expenses and trial expansion (Flamingo-01 into Europe), which could improve probability of success and de-risk timelines.

Key entities

  • Greenwich LifeSciences, Inc.

    Pre-revenue biotech reporting widened net loss, higher R&D costs, and cash of $5.9M at Sept. 30, 2026, while expanding Phase III Flamingo-01 into Europe.

  • GLSI-100 (Flamingo-01)

    Phase III trial evaluating prevention of breast cancer recurrence, expanding into Europe with plans for up to 150 global sites.

Related articles

$GLSIMedAI 8/10

RedChip Companies, Inc.: Greenwich LifeSciences Interview to Air Nationally on the RedChip Small Stocks, Big Money Show on CNBC and Bloomberg TV

Greenwich LifeSciences (GLSI) will be featured on the RedChip Small Stocks, Big Money show on Bloomberg TV and CNBC. CEO Snehal Patel discusses GLSI-100, an immunotherapy for HER2-positive breast cancer, highlighting an 80% reduction in recurrence in trials. The company is expanding its Phase III trial and exploring broader patient eligibility. GLSI aims to double its target population to 88,000 patients in the U.S. and Europe.

$GLSIMedAI 8/10

Greenwich LifeSciences presents at BIO-Europe 2026 in Cologne

Greenwich LifeSciences (GLSI) presented at BIO-Europe 2026, discussing its phase three trial (Flamingo-1) for early breast cancer. The trial, led by Baylor College of Medicine, has 180 sites in the US and Europe, with plans to expand. The company reported an 80% reduction in recurrence rate in phase two trials. GLSI is publicly traded, has raised $60M since IPO, and is fast track designated. Management owns 75-85% of the company, with a low float and extended lockup until January 2027.

$GLSIMedAI 8/10

Greenwich Advances FLAMINGO-01 Phase III Trial With Strategic Enrollment Changes

Greenwich LifeSciences (GLSI) said U.S. and European regulators approved changes to its FLAMINGO-01 Phase III trial of GLSI-100 for breast cancer recurrence. The DSMB recommended continuing without changes. Enrollment now includes non-HLA-A*02 patients, expected to more than double enrollment rate. In a 250-patient arm, preliminary results show a 70-80% recurrence reduction. Cash was about $8.9M at June 30, 2026.